Company news
Rein Therapeutics, Inc. news in 2022
Rein Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements
November 29, 2022
Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split
November 9, 2022
Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
October 31, 2022
Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles at EORTC-NCI-AACR International Conference
October 25, 2022
Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022
September 29, 2022
Aileron Therapeutics to Present and Participate in a Fireside Chat at the Ladenburg Thalmann 2022 Healthcare Conference
September 21, 2022
Aileron Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 5, 2022
Aileron Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
August 14, 2022
Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer
July 31, 2022
Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022
July 7, 2022
Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer
June 28, 2022
Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer
May 18, 2022
Aileron Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 16, 2022
Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022
May 12, 2022
Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upcoming Society for Investigative Dermatology 2022 Ann...
May 9, 2022
Aileron Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
May 4, 2022
Aileron Expands Management Team with Appointment of Christopher Zergebel As Vice President, Program Management and Clinical Operations
April 20, 2022
Aileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights
March 27, 2022
Aileron Therapeutics to Participate in Maxim Group 2022 Virtual Growth Conference
March 21, 2022
Aileron Therapeutics Provides Business Update and Outlines 2022 Strategic Priorities to Deliver Key Milestones
January 4, 2022
Aileron Therapeutics to Present at Upcoming Investor Conferences
January 3, 2022